• Recently, BioMarin Pharmaceutical discontinued three Phase 2 Voxzogo studies following safety concerns, while simultaneously reporting encouraging clinical and real-world outcomes for the drug in other settings.
• The company and analysts now suggest that Voxzogo’s safety issues may be limited to specific uses, with BioMarin’s broader outlook increasingly supported by its wider rare-disease portfolio.
• Now we’ll explore how the Voxzogo safety-driven trial discontinuations, alongside positive ongoing data, may reshape BioMarin’s investment narrative.

We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

BioMarin Pharmaceutical Investment Narrative Recap

To own BioMarin, you need to believe its rare-disease portfolio can offset concentration risk in a few key products, particularly Voxzogo. The Phase 2 Voxzogo trial discontinuations highlight safety vigilance, but current data and commentary suggest the immediate growth story still leans more on ongoing achondroplasia use and the broader pipeline than on those halted indications. Near term, the biggest risk remains regulatory or clinical setbacks in core programs rather than this specific safety signal.

Among recent updates, the new Voxzogo data presented in March 2026 stand out here. BioMarin reported sustained growth and improved body proportions with early treatment in achondroplasia, and a safety profile consistent with prior findings. Set against the halted Phase 2 studies, this mix of positive, indication-specific data and discrete safety concerns could influence how much weight you put on Voxzogo versus the rest of the portfolio as potential future growth drivers.

Yet, while Voxzogo’s growth story once seemed straightforward, investors should now be aware of emerging safety complexity that could...

BioMarin Pharmaceutical's narrative projects $3.8 billion revenue and $1.1 billion earnings by 2028. This requires 7.6% yearly revenue growth and a roughly $400 million earnings increase from $657.2 million today.

Uncover how BioMarin Pharmaceutical's forecasts yield a $88.96 fair value, a 62% upside to its current price.

Exploring Other Perspectives

Before this safety news, the most optimistic analysts were assuming BioMarin could reach about US$4.2 billion in revenue and US$1.4 billion in earnings by 2028, but if you worry that concentrated bets on Voxzogo and a few late stage assets could be disrupted by clinical surprises like these Phase 2 discontinuations, it is worth remembering that reasonable people can look at the same numbers and reach very different conclusions about BioMarin’s future path.

Explore 6 other fair value estimates on BioMarin Pharmaceutical - why the stock might be worth over 3x more than the current price!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your BioMarin Pharmaceutical research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free BioMarin Pharmaceutical research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate BioMarin Pharmaceutical's overall financial health at a glance.

No Opportunity In BioMarin Pharmaceutical?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 21 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• Capitalize on the AI infrastructure supercycle with our selection of the 35 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.